The 50-day moving average for LIMN moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LIMN as a result. In 34 of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 32%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LIMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for LIMN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 29 of 61 cases where LIMN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 48%.
Following a +9.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where LIMN advanced for three days, in 53 of 90 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
LIMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.349) is normal, around the industry mean (3.498). P/E Ratio (-0.106) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. LIMN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LIMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Moving Average Convergence Divergence (MACD) for UPB turned positive on October 28, 2026. Looking at past instances where UPB's MACD turned positive, the stock continued to rise in 19 of 22 cases over the following month. The odds of a continued upward trend are 86%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where UPB's RSI Indicator exited the oversold zone, 7 of 11 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on UPB as a result. In 17 of 26 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
Following a +11.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where UPB advanced for three days, in 85 of 103 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 17 of 19 cases where UPB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UPB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
UPB broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for UPB entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.653) is normal, around the industry mean (3.498). P/E Ratio (-1.122) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (91.743) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. UPB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UPB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
| LIMN | UPB | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 64% |
| Stochastic ODDS (%) | 2 days ago 48% | 2 days ago 89% |
| Momentum ODDS (%) | 7 days ago 32% | 2 days ago 65% |
| MACD ODDS (%) | N/A | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 48% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 55% | 2 days ago 86% |
| Advances ODDS (%) | 2 days ago 59% | 3 days ago 83% |
| Declines ODDS (%) | 6 days ago 73% | 27 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 57% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 55% | 2 days ago 88% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LIMN’s FA Score shows that 1 FA rating(s) are green while UPB’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LIMN’s TA Score shows that 3 TA indicator(s) are bullish while UPB’s TA Score has 4 bullish TA indicator(s).
LIMN (@Biotechnology) experienced а -0.72% price change this week, while UPB (@Biotechnology) price change was -0.29% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
LIMN is expected to report earnings on Nov 12, 2026.
UPB is expected to report earnings on Nov 11, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, LIMN has been loosely correlated with FTH. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if LIMN jumps, then FTH could also see price increases.
| Ticker / NAME | Correlation To LIMN | 1D Price Change % | ||
|---|---|---|---|---|
| LIMN | 100% | +2.59% | ||
| FTH - LIMN | 35% Loosely correlated | +1.89% | ||
| UPB - LIMN | 35% Loosely correlated | -5.59% | ||
| IMMP - LIMN | 34% Loosely correlated | -8.95% | ||
| RNA - LIMN | 32% Poorly correlated | -1.79% | ||
| ALDX - LIMN | 31% Poorly correlated | -1.08% | ||
More | ||||
A.I.dvisor indicates that over the last year, UPB has been loosely correlated with ARVN. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if UPB jumps, then ARVN could also see price increases.
| Ticker / NAME | Correlation To UPB | 1D Price Change % | ||
|---|---|---|---|---|
| UPB | 100% | -5.59% | ||
| ARVN - UPB | 38% Loosely correlated | +2.37% | ||
| IMNM - UPB | 37% Loosely correlated | -3.67% | ||
| IRON - UPB | 36% Loosely correlated | +4.16% | ||
| LIMN - UPB | 35% Loosely correlated | +2.59% | ||
| SLDB - UPB | 34% Loosely correlated | +2.14% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IAK | 152.23 | 2.27 | +1.51% |
| iShares U.S. Insurance ETF (IAK) | |||
| UMAR | 43.15 | -0.10 | -0.22% |
| Innovator U.S. Equity Ultra Buffer ETF - March (UMAR) | |||
| NUGY | 11.07 | -0.04 | -0.35% |
| GraniteShares YieldBOOST Gold Miners ETF (NUGY) | |||
| VNQI | 43.83 | -0.29 | -0.66% |
| Vanguard Global ex-U.S. Real Estate ETF (VNQI) | |||
| NYSX | 23.45 | -0.21 | -0.90% |
| Global X NYSE 100 ETF (NYSX) | |||